Use of Molecular Mutations in High Risk MPN for Assessment of Blastic Transformation

Pathology- United States

doi 10.1016/j.pathol.2020.01.387

Full Text

Abstract

Available in

Date

Authors

Publisher

Elsevier BV

Related search

Toward a Molecular Equivalent Dose: Use of the Medaka Model in Comparative Risk Assessment

Comparative Biochemistry and Physiology Part - C: Toxicology and Pharmacology
Cell BiologyBiochemistryMedicineAnimal ScienceMutagenesisHealthAquatic ScienceZoologyToxicologyPhysiology
2009English

Ecological Risk Assessment for Use of Agricultural Rodenticides in California

Proceedings of the Vertebrate Pest Conference
2006English

Use of Influenza Risk Assessment Tool for Prepandemic Preparedness

Emerging Infectious Diseases
EpidemiologyInfectious DiseasesMicrobiology
2018English

Bioinformatics Assessment of Β-Myosin Mutations Reveals Myosin's High Sensitivity to Mutations

Trends in Cardiovascular Medicine
Cardiovascular MedicineCardiology
2008English

Driver Mutations and Prognosis in Primary Myelofibrosis: Mayo-Careggi MPN Alliance Study of 1,095 Patients

American Journal of Hematology
Hematology
2017English

Sequential B-Lymphoid and Myeloid Blastic Transformation of Philadelphia Chromosome-Negative Myeloproliferative Neoplasm

British Journal of Haematology
Hematology
2018English

Risk Assessment Methodology in the Use of Mobile Phones

2015English

Assessment and Treatment of Individuals at High Risk for Psychosis

BJ Psych Advances
PsychiatryMental Health
2019English

Guidance on Commodity Risk Assessment for the Evaluation of High Risk Plants Dossiers

EFSA Journal
VeterinaryMicrobiologyFood ScienceAnimal ScienceParasitologyPlant ScienceZoology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy